Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report) is expected to issue its quarterly earnings data before the market ...

Asthma a chronic respiratory condition may be driven by specific immune cells that influence inflammation and severity ...

If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the ...

(Reuters) - A newly discovered bat coronavirus uses the same cell-surface protein to gain entry into human cells as the ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its ...

The study showed that medicine used to help asthma patients for more than 20 years could lessen or prevent acute allergic ...

Monoclonal antibodies are novel therapeutic ... their efficacy and between the agents themselves. Antibodies against B cells Rituximab is a depleting antibody directed against CD20 on the surface ...